Phibro Animal Health Corporation (PAHC)

Market Cap	947.38M
Revenue (ttm)	1.05B
Net Income (ttm)	17.41M
Shares Out	40.50M
EPS (ttm)	0.43
PE Ratio	54.43
Forward PE	13.65
Dividend	$0.48 (2.05%)
Ex-Dividend Date	Sep 4, 2024

Volume	223,832
Open	23.55
Previous Close	23.75
Day's Range	23.09 - 23.64
52-Week Range	9.49 - 25.98
Beta	0.51
Analysts	Sell
Price Target	19.00 (-18.77%)
Earnings Date	Nov 6, 2024

About PAHC

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs. It also offers animal health products, such as antibacterials, anticoccidials, nutritional specialty, and vaccines and vaccine...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Apr 11, 2014
• Employees: 1,940
• Stock Exchange: NASDAQ
• Ticker Symbol: PAHC
• Website: https://www.pahc.com

Financial Performance

In 2024, Phibro Animal Health's revenue was $1.02 billion, an increase of 4.07% compared to the previous year's $977.89 million. Earnings were $2.42 million, a decrease of -92.59%.

Analyst Forecast

According to 3 analysts, the average rating for PAHC stock is "Sell." The 12-month stock price forecast is $19.0, which is a decrease of -18.77% from the latest price.

Price Target

$19.0

(-18.77% downside)

Analyst Consensus: Sell